Eiger BioPharmaceuticals (STU:72C) Net Margin %: -449.00% (As of Dec. 2023)


STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals Net Margin %?

Eiger BioPharmaceuticals STU:72C 10 Net Margin % is -449.00% as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Net margin is calculated as Net Income divided by its Revenue. Eiger BioPharmaceuticals's Net Income for the six months ended in Dec. 2023 was €-28.87 Mil. Eiger BioPharmaceuticals's Revenue for the six months ended in Dec. 2023 was €6.43 Mil. Therefore, Eiger BioPharmaceuticals's net margin for the quarter that ended in Dec. 2023 was -449.00%.

The historical rank and industry rank for Eiger BioPharmaceuticals's Net Margin % or its related term are showing as below:


STU:72C's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.09
* Ranked among companies with meaningful Net Margin % only.

Eiger BioPharmaceuticals  (STU:72C) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Eiger BioPharmaceuticals Net Margin % Related Terms

Eiger BioPharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Net Margin % Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -279.33 -717.71 -475.26

Eiger BioPharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -658.27 -777.47 -496.30 -449.00 -2,339.51

STU:72C vs EDSA, SIGY, EVLO: Net Margin % Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eiger BioPharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Net Margin % falls into.


STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Eiger BioPharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-68.741/14.464
=-475.26 %

Eiger BioPharmaceuticals's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-28.871/6.43
=-449.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -449.00% mean?
Eiger BioPharmaceuticals (STU:72C) has a Net Margin % of -449.00% as of Dec. 2023. Net margin is the ratio of total net income to net sales. View historical data on Eiger BioPharmaceuticals and its competitors.
Is Eiger BioPharmaceuticals' Net Margin % too high?
Eiger BioPharmaceuticals' current Net Margin % is -449.00%. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Net Margin % compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Net Margin % of -449.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Net Margin % is -449.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Net Margin % of -449.00%. The current Net Margin % is -449.00%. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Net Margin % is -449.00% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price